Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01923389 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01923389: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT01923389 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01923389, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
Primary Outcome
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were also reported for the 7-day pre-randomization period.
Interventions
- OTHER Placebo
- DRUG 100 mg PF-05231023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Why NCT01923389 stopped before completion
NCT01923389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01923389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01923389 about?
NCT01923389 is a clinical study titled "Multiple Dose Study Of PF-05231023 In Obese Adult Subjects". This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
What is the current status of trial NCT01923389?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2013-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01923389?
The interventions under investigation include: Placebo (OTHER), 100 mg PF-05231023 (DRUG).
Who is sponsoring clinical trial NCT01923389?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01923389's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia